Vertex Pharmaceuticals (VRTX) Revenue — Quarter Ended Mar 31, 2025
Vertex Pharmaceuticals reported a revenue decline for the quarter compared to the immediately preceding period. Revenue rose relative to the same quarter one year earlier.
Key takeaway
Quarter ended Mar 31, 2025 · FY2025 Q1
Vertex Pharmaceuticals reported a revenue decline for the quarter compared to the immediately preceding period. Revenue rose relative to the same quarter one year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.8B
Revenue reported for this quarter.
Quarter-over-quarter
-4.9%
Change from the immediately preceding quarter.
Year-over-year
+3.0%
Change from the comparable year-ago quarter.
Trailing four quarters
$11.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2024 | $2.6B | +6.1% |
| Sep 30, 2024 | $2.8B | +11.6% |
| Dec 31, 2024 | $2.9B | +15.7% |
| Mar 31, 2025 | $2.8B | +3.0% |
Revenue performance
Total revenues decreased from the prior quarter, driven by lower product revenues. The year-over-year increase in product revenues was partially offset by higher costs.
Quarterly comparison
Compared to the prior quarter, revenue contracted. Compared to the same quarter a year ago, revenue expanded, though at a slower rate than recent sequential quarters.
What to watch
The shift from sequential growth to a decline warrants monitoring for any sustained trend.